


## PHARMACEUTICAL 2021



## VERTEX PHARMACEUTICALS INC MA Rank 7 of 409







## PHARMACEUTICAL 2021



## VERTEX PHARMACEUTICALS INC MA Rank 7 of 409



The relative strengths and weaknesses of VERTEX PHARMACEUTICALS INC MA are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of VERTEX PHARMACEUTICALS INC MA compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 449% points. The greatest weakness of VERTEX PHARMACEUTICALS INC MA is the variable Cost of Goods Sold, reducing the Economic Capital Ratio by 19% points.

The company's Economic Capital Ratio, given in the ranking table, is 276%, being 630% points above the market average of -355%.

Input Variable	Value in 1000 USD
Assets, Current	8,133,379
Cost of Goods Sold	736,300
Intangible Assets	1,402,158
Liabilities, Current	1,877,533
Liabilities, Non-Current	458,818
Other Assets	2,216,271
Other Compr. Net Income	-66,507
Other Expenses	476,402
Other Liabilities	728,642
Other Net Income	318,659
Property and Equipment	0
Research and Development	1,829,537
Revenues	6,205,683
Selling, General and Administrative Expense	770,456

Output Variable	Value in 1000 USD
Assets	11,751,808
Liabilities	3,064,993
Expenses	3,812,695
Stockholders Equity	8,686,815
Net Income	2,711,647
Comprehensive Net Income	2,678,394
Economic Capital Ratio	276%